Injection Site Responses in Tigilanol Tiglate Trials: Local Reactions and Wound Healing Timelines

Intratumoural injection of tigilanol tiglate produces a characteristic local response at the injection site, and managing that response is a central theme of the published Phase I and Phase II clinical trial literature. For readers tracking the science behind EBC-46, understanding the injection-site reaction profile and wound-healing timeline offers important context on how the compound behaves in patients — and why oral dietary supplements and injectable pharmaceuticals are distinct product categories.

What the local response looks like

After intratumoural administration, tigilanol tiglate produces rapid tumour cell death and localised haemorrhagic necrosis. Clinically, this presents as swelling, erythema, bruising, and often visible sloughing of the tumour mass within hours to days. The reaction is expected, time-limited, and part of the intended pharmacological effect — not an allergic or idiosyncratic adverse event. Published trial data and the veterinary product label describe it as the primary manifestation of on-target activity.

Wound healing timeline

Trial reports describe a generally predictable wound-healing sequence:

• Days 0–3: acute oedema, erythema, and tumour necrosis become visible
• Days 3–14: necrotic tissue demarcates and begins to slough; wound bed forms
• Weeks 2–6: granulation tissue fills the defect and re-epithelialisation progresses
• Weeks 6–12: contraction and closure, typically without surgical intervention for small-to-moderate lesions

Larger tumours or lesions in anatomically awkward sites may take longer and occasionally require supportive wound care. The published Phase I data in patients with soft-tissue tumours characterises the timeline as dose-dependent and tumour-size-dependent but generally manageable with standard wound-care practice.

Adverse event profile

Reported adverse events in the human Phase I and Phase II data are predominantly injection-site related (pain, oedema, localised bleeding, occasional wound infection) rather than systemic. Systemic exposure following intratumoural administration is low in the published pharmacokinetic data, which is consistent with the rapid local distribution and limited plasma half-life of the compound. Trial authors have highlighted this pharmacokinetic profile as one of the reasons the approach is being explored further.

Grading of injection-site reactions in the published studies has broadly followed the Common Terminology Criteria for Adverse Events (CTCAE) framework, which is the standard used across oncology trials. Most events have been graded as mild to moderate, with a smaller proportion requiring targeted wound-care management. None of the published human trials have reported treatment-related deaths attributable to tigilanol tiglate injection itself.

Patient selection considerations

The trial literature discusses patient selection criteria that have evolved across studies: tumour accessibility (cutaneous or subcutaneous lesions), tumour size relative to surrounding structures, coagulation status, and wound-healing capacity. Patients with impaired healing or lesions adjacent to major vessels require tailored assessment. These are clinical trial considerations and do not translate to dietary supplement use.

Veterinary context

The injection-site reaction profile in humans is broadly similar to that observed with Stelfonta, the FDA-approved veterinary tigilanol tiglate product indicated for mast cell tumours in dogs. Published veterinary outcome data describes a comparable time course for wound formation, demarcation, and healing. This parallel provides a useful real-world reference point for clinicians managing human-trial patients.

Relevance to dietary supplements

Injection-site response data comes from pharmaceutical-grade tigilanol tiglate administered directly into a tumour. Oral dietary supplements containing whole-seed blushwood berry extract are a wholly separate product category regulated under DSHEA and equivalent frameworks. They are not intended to diagnose, treat, cure, or prevent any disease, and they are not administered by injection.

Suppliers such as Blushwood Health position their products unambiguously within the dietary-supplement category, with Eurofins-accredited batch testing and GMP-certified manufacturing. Keeping these two product categories distinct is important for accurate reading of both the clinical trial literature and consumer supplement information.

Related reading

See our coverage of RECIST criteria used in tigilanol tiglate trials and long-term follow-up and recurrence data.

Citations

1. Panizza BJ et al. — Phase I dose-escalation study of intratumoural tigilanol tiglate in cutaneous/subcutaneous tumours, eClinicalMedicine, 2019.

2. FDA — Approval of Stelfonta (tigilanol tiglate) for canine mast cell tumours, 2020.

3. QBiotics Group — Tigilanol tiglate programme overview, accessed 2026.